The Effectiveness of Self-Control and Anxiety Management Training to Reduce Anxiety and Improve Health-Related Quality of Life in Children with Asthma

2015 ◽  
Vol 05 (06) ◽  
Author(s):  
Walaa A Abd Elfatah
2013 ◽  
Vol 56 (1) ◽  
pp. 83-85 ◽  
Author(s):  
William W. Wong ◽  
Sarah E. Barlow ◽  
Carmen Mikhail ◽  
Theresa A. Wilson ◽  
Paula M. Hernandez ◽  
...  

2012 ◽  
Vol 24 (3) ◽  
pp. 472-489 ◽  
Author(s):  
Alison Crosbie

ObjectiveAsthma is a leading cause of chronic illness in children, impacting heavily on their daily life and participation in physical activity. The purpose of this systematic review was to investigate the evidence for the use of physical therapy to improve pulmonary function and aerobic capacity in children with asthma. Furthermore, the review aims to update previous literature on the effect of exercise on health related quality of life.MethodsA search was conducted for randomized control trials (RCTs) using the electronic databases Medline, Embase, SPORTDiscus, AMED, CINAHL, and The Cochrane Central Register of Controlled Trials. Studies were included if the participants were asthmatic children aged 6–18 years participating in any mode of physical exercise. Studies were reviewed for study quality, participant details, exercise intervention details, and intervention outcomes.ResultsA total of 16 studies and 516 subjects met inclusion criteria for review. Severity of asthma ranged from mild to severe. No improvement in pulmonary function was observed. Physical training led to an increase in aerobic capacity as measured by VO2max (mL/kg/min).ConclusionsFindings suggest that physical training does not improve pulmonary function in children with asthma, but does increase aerobic capacity. The small number of studies investigating quality of life suggests that physical training does improve health related quality of life; however further well designed randomized control trials are needed to verify these findings.


2019 ◽  
Vol 39 (03) ◽  
pp. 272-278
Author(s):  
Cindy E. Neunert

AbstractManagement of patients with corticosteroid-refractory immune thrombocytopaenia (ITP) possesses a significant challenge to practitioners. Until recently, options included splenectomy and immunosuppression. With improved knowledge of both thrombopoiesis and the pathophysiology of ITP, novel drug development with thrombopoietin-receptor agonists (TPO-RAs) was undertaken. Two agents, romiplostim and eltrombopag, are currently approved for use in patients with chronic ITP. Both agents have been shown to increase the platelet count, improve health-related quality of life and reduce bleeding symptoms and concomitant medication use. This review will highlight the discovery of TPO-RA agents, appraise key clinical trials and explore future directions.


2019 ◽  
Vol 100 (5) ◽  
pp. 923-930 ◽  
Author(s):  
Anson B. Rosenfeldt ◽  
Susan M. Linder ◽  
Sara Davidson ◽  
Cynthia Clark ◽  
Nicole M. Zimmerman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document